These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Alcindor T; Witzig TE Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764 [TBL] [Abstract][Full Text] [Related]
5. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Marcus R Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024 [TBL] [Abstract][Full Text] [Related]
6. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Grillo-López AJ Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025 [TBL] [Abstract][Full Text] [Related]
7. Development of 131I-tositumomab. Lewington V Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488 [TBL] [Abstract][Full Text] [Related]
10. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]. Emmanouilides C Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013 [TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Macklis RM Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564 [TBL] [Abstract][Full Text] [Related]
12. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Borghaei H; Wallace SG; Schilder RJ Clin Lymphoma; 2004 Oct; 5 Suppl 1():S16-21. PubMed ID: 15498145 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Witzig TE Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398 [TBL] [Abstract][Full Text] [Related]
15. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Winter JN Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146 [TBL] [Abstract][Full Text] [Related]
16. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Vose JM Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920 [TBL] [Abstract][Full Text] [Related]
17. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS; Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803 [TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]